MAP7D1

Across TCGA pan-cancer cohorts, MAP7D1 mass-spec protein is linked to patient survival in 8 of 34 cancer types, making it a survival-associated MAP7D1 data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MAP7D1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MAP7D1 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

CCRCC, PDAC, and COAD are the cancer types where MAP7D1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	III,IV	0.696	1.000	.009	23	view →
PDAC	OS	Median	All	0.345	0.638	<.001	12	view →
COAD	DFS	Quartile	III,IV	0.791	1.000	.036	6	view →
UCEC	DFS	Quartile	All	0.801	0.969	.049	4	view →
LSCC	OS	Tertile	All	0.674	1.000	.012	3	view →
HNSC	DFS	Median	III,IV	1.000	0.937	.035	2	view →
GBM	DFS	Tertile	All	0.236	0.452	.043	2	view →
LUAD	DFS	Median	All	0.956	0.882	.031	1	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

MAP7D1–CCRCC (OS)

Open the CCRCC breakdown →